$TWST: Twist Bioscience Is Up 566% and Now Trades Above Wall Street's Raised Target. It All Rides on November 13.

Twist Bioscience closed Thursday's session, September 24, up 16.1%, a $25.53 move to $184.03, and led the entire market higher on the day (Nasdaq: TWST). That was not a one-day event dropped onto a quiet stock. It capped a powerful multi-week run and a 52-week gain of roughly 566%, from a low of $23.30 to Thursday's fresh intraday high of $185.22. A DNA-synthesis company that spent years as a speculative, heavily shorted life-sciences name is now a $11.5 billion company, and it got there in twelve months.

The proximate trigger was Wall Street, not the company. Leerink Partners reiterated a Buy rating and raised its price target to $160, and its note tied Twist to the hottest theme in biotech right now: artificial intelligence applied to protein and antibody design. The catalyst underneath that call is a real, dated corporate development. In mid-September, Twist joined Eli Lilly's TuneLab, the AI and machine-learning drug-discovery platform Lilly has opened to outside biotechs, in a role supplying synthesis and data into that ecosystem. Layer on the broader narrative, including Anthropic's published work on using its Claude models to accelerate protein design, and the market has recast Twist from a picks-and-shovels tools vendor into a direct beneficiary of the AI-drug-discovery buildout.

Here is the tension worth twenty minutes of your attention. The stock now trades above Leerink's freshly raised bull target. It changes hands at nearly 27 times trailing sales for a company that is still losing money, with a relative strength index of 74 and a beta of 2.22. And roughly one in five shares outstanding is sold short. That combination, a genuine fundamental inflection, an AI narrative, a parabolic chart, and a large short base, is exactly the setup where the next scheduled event decides everything. For Twist that event has a date: November 13, 2026, when the company reports fiscal fourth-quarter and full-year results, the very quarter management guided to reach adjusted-EBITDA breakeven.

The question the price is asking, and the one the next fifty days will answer, is whether the fundamentals can grow into a valuation that has already priced the AI story as a near-certainty.

Get the next briefing free in your inbox: Join AlphaBriefing

The rest of this briefing is for paid members: the real share-count and valuation math behind the $11.5 billion tag, what the Lilly TuneLab role does and does not guarantee, the balance-sheet clock and the November 13 breakeven test, the 19% short position and what it does in each direction, and scenario-by-scenario price zones.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →